comparemela.com
Home
Live Updates
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook : comparemela.com
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy.
– Preliminary unaudited Q4 and full year 2023...
Related Keywords
Jordan ,
China ,
Dustin Sjuts ,
Markj Foley ,
Viatris Inc ,
Peptide Exchange Technology ,
Exchange Commission ,
Foley ,
Securities Exchange ,
Revance Therapeutics Inc ,
Linkedin ,
Decision Resources Group Aesthetics Injectables Botulinum Toxin ,
Nasdaq ,
Decision Resources Group Market Analysis ,
Revance Therapeutics ,
Chief Executive Officer ,
Marketing Approval ,
Erica Jordan ,
Chief Commercial Officer ,
Financial Outlook ,
Boxed Warning ,
Distant Spread ,
Specific Populations ,
Prescribing Information ,
Shanghai Fosun Pharmaceutical ,
Resilient Hyaluronic Acid ,
Private Securities Litigation Reform Act ,
Securities Act ,
Securities Exchange Act ,
Cervical Dystonia ,
Markets ,
comparemela.com © 2020. All Rights Reserved.